CYTOAGENTS, INC.

CTO1681 to prevent and mitigate cytokine release syndrome in CAR T-cell recipients

CYTOAGENTS, INC. operates in national cancer institute based in PITTSBURGH, PA, founded in 2018.

Profile

Abstract
CytoAgents is developing CTO1681 for the prevention and treatment of cytokine release syndrome (CRS)
associated with chimeric antigen receptor (CAR) T-cell therapy. CAR T-cell therapy has emerged as a very
promising treatment option for patients with relapsed or refractory (R/R) hematologic malignancies. However,
CAR T-cell therapy can also result in a high incidence of severe and potentially life-threatening immune-mediated
toxicity, including CRS and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS is a systemic
inflammatory response that has been reported as one of the most frequent and dangerous adverse events
following CD19-directed CAR T-cell therapy. CRS is thought to be mediated by an initial release of
proinflammatory cytokines, which activate bystander immune cells and endothelial cells, which in turn activate
more immune cells, culminating in a cytokine storm. Because CytoAgents’ novel approach is focused on
reducing the transcription of multiple proinflammatory cytokines, its compound is expected to mitigate,
and in some cases even prevent, CRS. CTO1681 is an orally available, stable compound identical to beraprost
sodium-314d (BPS-314d), the stereoisomer of the racemate beraprost sodium (BPS) that accounts for nearly all
of BPS’s pharmacological activity. Because BPS can modulate the release of cytokines from human peripheral
blood monon

Its activity falls under national cancer institute; the profile below is assembled from public directory data.

The company is recorded as being based in PITTSBURGH, PA.

Its current recorded stage is SBIR/STTR.

Recorded headcount: 1-10 employees.

It has disclosed roughly $1M in funding.

Website: cytoagents.com